Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6–34. https://doi.org/10.1038/s41572-021-00245-6

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Hou JL, Zhao W, Lee C et al (2020) Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol 18:457–467. https://doi.org/10.1016/j.cgh.2019.07.010

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681–693. https://doi.org/10.1016/j.jhep.2021.11.018

Article  PubMed  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390. https://doi.org/10.1056/NEJMoa0708857

Article  CAS  PubMed  Google Scholar 

Strumberg D (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41:773–784. https://doi.org/10.1358/dot.2005.41.12.937959

Article  CAS  PubMed  Google Scholar 

Li Y, Gao ZH, Qu XJ (2015) The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol 116:216–221. https://doi.org/10.1111/bcpt.12365

Article  CAS  PubMed  Google Scholar 

Zhang H, Shang YP, Chen HY et al (2017) Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res 47:149–159. https://doi.org/10.1111/hepr.12757

Article  CAS  PubMed  Google Scholar 

Woo YM (2016) Epigenetic Regulation in Cystogenesis. Adv Exp Med Biol 933:59–68. https://doi.org/10.1007/978-981-10-2041-4_6

Article  CAS  PubMed  Google Scholar 

Chen HP, Zhao YT, Zhao TC (2015) Histone deacetylases and mechanisms of regulation of gene expression. Crit Rev Oncog 20:35–47. https://doi.org/10.1615/critrevoncog.2015012997

Article  PubMed  PubMed Central  Google Scholar 

Quint K, Agaimy A, Di Fazio P et al (2011) Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 459:129–139. https://doi.org/10.1007/s00428-011-1103-0

Article  CAS  PubMed  Google Scholar 

Freese K, Seitz T, Dietrich P et al (2019) Histone deacetylase expressions in hepatocellular carcinoma and functional effects of histone deacetylase inhibitors on liver cancer cells in vitro. Cancers (Basel) 11:1587–1606. https://doi.org/10.3390/cancers11101587

Article  CAS  PubMed  Google Scholar 

Stepulak A, Stryjecka-Zimmer M, Kupisz K et al (2005) Inhibitory deacetylaz histonów jako potencjalne cytostatyki nowej generacji [Histone deacetylase inhibitors as a new generation of anti-cancer agents]. Postepy Hig Med Dosw (Online) 59:68–74

PubMed  Google Scholar 

Frew AJ, Johnstone RW, Bolden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280:125–133. https://doi.org/10.1016/j.canlet.2009.02.042

Article  CAS  PubMed  Google Scholar 

Ververis K, Hiong A, Karagiannis TC et al (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47–60. https://doi.org/10.2147/BTT.S29965

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyanaga A, Gemma A, Noro R et al (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7:1923–1930. https://doi.org/10.1158/1535-7163.MCT-07-2140

Article  CAS  PubMed  Google Scholar 

Turtoi A, Peixoto P, Castronovo V et al (2015) Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives. Crit Rev Oncog 20(1–2):119–137. https://doi.org/10.1615/critrevoncog.2014012423

Article  PubMed  Google Scholar 

Liu T, Kuljaca S, Tee A et al (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32:157–165. https://doi.org/10.1016/j.ctrv.2005.12.006

Article  CAS  PubMed  Google Scholar 

Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39. https://doi.org/10.1182/blood-2006-06-025999

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woo S, Gardner ER, Chen X et al (2009) Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 15:1496–1503. https://doi.org/10.1158/1078-0432.CCR-08-1215

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor OA, Horwitz S, Masszi T et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33:2492–2499. https://doi.org/10.1200/JCO.2014.59.2782

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi Y, Jia B, Xu W et al (2017) Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol 10:69–74. https://doi.org/10.1186/s13045-017-0439-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sivaraj D, Green MM, Gasparetto C (2017) Panobinostat for the management of multiple myeloma. Future Oncol 13:477–488. https://doi.org/10.2217/fon-2016-0329

Article  CAS  PubMed  Google Scholar 

Marx-Blümel L, Marx C, Kühne M et al (2017) Assessment of HDACi-induced cytotoxicity. Methods Mol Biol 1510:23–45. https://doi.org/10.1007/978-1-4939-6527-4_3

Article  CAS  PubMed  Google Scholar 

Benedetti R, Conte M, Altucci L (2015) Targeting histone deacetylases in diseases: where are we? Antioxid Redox Signal 23:99–126. https://doi.org/10.1089/ars.2013.5776

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jenke R, Reßing N, Hansen FK et al (2021) Anticancer therapy with hdac inhibitors: mechanism-based combination strategies and future perspectives. Cancers (Basel) 13:634–677. https://doi.org/10.3390/cancers13040634

Article  CAS  PubMed  Google Scholar 

Yang K, Song Y, Xie H et al (2018) Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg Med Chem Lett 28:2493–2497. https://doi.org/10.1016/j.bmcl.2018.05.057

Article  CAS  PubMed  Google Scholar 

Chowdhury A, Marin A, Weber DJ et al (2021) Nano-assembly of quisinostat and biodegradable macromolecular carrier results in supramolecular complexes with slow-release capabilities. Pharmaceutics 13:1834–1849. https://doi.org/10.3390/pharmaceutics13111834

Article  CAS  PubMed  PubMed Central  Google Scholar